Gastrointestinal Cancer

Patient Characteristics Linked to Time on Treatment and Survival in Patients With mCRC Receiving Cetuximab

June 11, 2021

KRAS mutational status and geographical region were associated with time on treatment (TOT), and body mass index (BMI) and age were linked with overall survival (OS) in patients with metastatic colorectal cancer mCRC) being treated with second-line cetuximab (Erbitux) after irinotecan or oxaliplatin-based regimens.